Day: December 8, 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated